Conference
Evaluation of second-line response to targeted therapy following progression on first-line cediranib, an oral pan-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), in advanced renal cell carcinoma (RCC).
Authors
Richter S; Gan HK; MacKenzie MJ; Hotte SJ; Mukherjee SD; Kollmannsberger CK; Ivy SP; Fernandes K; Halford R; Massey C
Volume
29
Pagination
pp. e15153-e15153
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2011
DOI
10.1200/jco.2011.29.15_suppl.e15153
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X